Its finally out Nature Medicine ! Excited to share our work identifying an association between CAR-Tregs and relapse/resistance after CAR-T cell treatment in DLBCL via scRNAseq and then modeling it in vivo (along with much more!)

Unbelievably exciting to see the benefits of CAR-T being extended safely for non malignant conditions with high morbidity statnews.com/2022/09/15/lup…

Large propensity score matched study #axicel vs #tisacel in Nature Medicine by Emmanuel Bachy et al Closely matched large cohorts ⬆️ ORR, CR, PFS & OS advantage for #axicel pts 1 yr OS 63.5% vs 48.8% p=0.0072 ⬆️ G1-2 CRS, & all grade ICANS in #axicel pts #CART #lymsm #DLBCL

SPOTLIGHT: Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell #lymphoma Mark Leick Satyen Gohil Gaddy Getz Dr Marcela Maus. Originally published in Nature Medicine. To read our summary click ow.ly/zu6N50KVJTZ and scroll all the way down.

We're excited to share the 1st clinical experience delivering intracranial B7-H3 #CARTcells to treat #DIPG in Cancer Discovery, a journal of the AACR. #1: on behalf of Seattle Children's & Seattle Children's Therapeutics (SCTx), we are humbled by our patients' trust and bravery. (1/2) aacrjournals.org/cancerdiscover…

Thoughtful piece in Nature Medicine from Eddie Cliff, Reid Merryman, Philippe Armand and Caron Jacobson Harvard Medical School Dana-Farber on #CARTcells in #DLBCL. Thanks for writing this! #lymphoma #lymsm

If you assumed we are talking about CAR-T, you would be correct! Jae Park Dr Marcela Maus Mark Leick #ASH22

Hope you picked up your badge at the airport… 😬#ASH22

#ASH22 | La Nouvelle Orleans Ballroom AB | Saturday 2pm CST Patients With Deleterious Germline Variants in STXBP2 Develop Toxicity After CAR-T Cell Therapy With Axicabtagene Ciloleucel Mark B. Leick, MD (Mark Leick) ➡️ bit.ly/3HgELGC ASH

Great talk on germline HLH variants affecting CAR-T toxicity by Mark Leick Dr Marcela Maus , looking forward to collaborating! #ASH22 Frederick L. Locke

We are hiring! Interested in engineering, genomics and T cell therapies for cancer? Want to work with awesome people? Looking for a great place to live? Come join us in St Louis! More info about us here: sites.wustl.edu/nathansinghlab/ Apply here: wustl.wd1.myworkdayjobs.com/en-US/External… Please RT!

'Multiomics STEP up in correlative analysis of response to CAR T cells'. In this article, Mark Leick & Marcela Maus discuss the potential of cfDNA-based analyses to inform on CAR T cell expansion kinetics & tumour-infiltration patterns in patients: nature.com/articles/s4157…

If your ✈️ got cancelled ❄️, if you take one CAR-T review to a deserted island 🏝️, if you want to learn about CAR-Ts and don't know where to start... Louai Labanieh and Crystal Mackall Lab just published an epic review. nature.com/articles/s4158…

Happy to share the newest paper from our lab. Led by technician extraordinaire Aidan Tousley (soon to be an MD/PHD student!), this manuscript details our attempts to reimagine the structure of CARs to improve their specificity and efficacy. rdcu.be/c7avS

CAR-T coming for a non-malignant indication near you thelancet.com/journals/lance….

Really happy to see the wonderful work from colleagues in Rome using 3rd gen GD2 CARs for neuroblastoma. This is the largest series of CAR T responses in a solid tumor to date & the fact that it’s in a pediatric cancer is awesome! Bravo! nejm.org/doi/full/10.10…

🚨Next-level T cell engineering enters the clinic! DNA base editor to simultaneously silence CD7 (minimize fratricide), TCRB (minimize GVHD), and CD52 (host pre-conditioning) in allo CD7 CAR-expressing T cells for T-ALL. No DNA cuts, no translocations. nejm.org/doi/full/10.10…

Excited to share that Majzner_Lab is moving to Dana-Farber Dana-Farber/Boston Children's as of Sept. Bittersweet to leave Stanford, but looking forward to growing our research program both in the lab and in the clinic. Hiring postdocs, scientists & lab manager- please reach out if interested!

nejm.org/doi/full/10.10… Amazing findings coming out of the Maus lab! Great step forward to GBM treatment. Congrats to all the authors on their incredible work.

Today, NEJM published our clinical study of a novel #CARTCell in patients with #Glioblastoma. Early results with CARv3-TEAM-E suggest safety and bioactivity. Special thanks to all collaborators MGH Neurosurgery and Mass General Cancer Center! nej.md/3VnjUIq